Cargando…

A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates

BACKGROUND: Sorafenib monotherapy in patients with metastatic melanoma was explored in this multi-institutional phase II study. In correlative studies the impact of sorafenib on cyclin D1 and Ki67 was assessed. METHODOLOGY/PRINCIPAL FINDINGS: Thirty-six patients treatment-naïve advanced melanoma pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ott, Patrick A., Hamilton, Anne, Min, Christina, Safarzadeh-Amiri, Sara, Goldberg, Lauren, Yoon, Joanne, Yee, Herman, Buckley, Michael, Christos, Paul J., Wright, John J., Polsky, David, Osman, Iman, Liebes, Leonard, Pavlick, Anna C.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012061/ https://www.ncbi.nlm.nih.gov/pubmed/21206909 http://dx.doi.org/10.1371/journal.pone.0015588

Ejemplares similares

Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients
por: Yu, Jessie Z, et al.
Publicado: (2008)

Intra- and Inter-Tumor Heterogeneity of BRAF(V600E)Mutations in Primary and Metastatic Melanoma
por: Yancovitz, Molly, et al.
Publicado: (2012)

Clinical relevance of Neutral Endopeptidase (NEP/CD10) in melanoma
por: Velazquez, Elsa F, et al.
Publicado: (2007)

Clinical significance of BRAF mutations in metastatic melanoma
por: Chang, David Z, et al.
Publicado: (2004)

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
por: Buckley, Michael T, et al.
Publicado: (2007)

Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis
por: Weiss, Sarah, et al.
Publicado: (2015)

Increased shedding of HU177 correlates with worse prognosis in primary melanoma
por: Hamilton, Heather K, et al.
Publicado: (2010)

Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
por: Shah, Carl‐Henrik, et al.
Publicado: (2018)

Melanoma risk loci as determinants of melanoma recurrence and survival
por: Rendleman, Justin, et al.
Publicado: (2013)

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
por: Donnelly, Douglas, et al.
Publicado: (2019)

Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma
por: Usyk, Mykhaylo, et al.
Publicado: (2021)

A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma
por: Ott, Patrick A., et al.
Publicado: (2010)

Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM)
por: Ferguson, Robert, et al.
Publicado: (2019)

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
por: Fruehauf, John P., et al.
Publicado: (2018)

A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma
por: Uldrick, Thomas S., et al.
Publicado: (2017)

Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2017)

Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Shahda, Safi, et al.
Publicado: (2016)

Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)
por: Vera Aguilera, Jesus, et al.
Publicado: (2018)

Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
por: Dillman, Robert O, et al.
Publicado: (2019)

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
por: Piperno-Neumann, Sophie, et al.
Publicado: (2016)

Deletion of PTENP1 pseudogene in human melanoma
por: Poliseno, Laura, et al.
Publicado: (2011)

Validation of the prophylactic efficacy of urea‐based creams on sorafenib‐induced hand‐foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study
por: Lien, Ru‐Yu, et al.
Publicado: (2021)

Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients
por: Dréno, Brigitte, et al.
Publicado: (2021)

Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20
por: Patt, Yehuda, et al.
Publicado: (2017)

Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)
por: Ostwal, Vikas, et al.
Publicado: (2022)

Rand McNally guide to Mexico,
por: Liebes, Herman
Publicado: (1961)

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
por: Mao, Lili, et al.
Publicado: (2022)

A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
por: Janni, Wolfgang, et al.
Publicado: (2014)

Morphine promotes migration and lung metastasis of mouse melanoma cells
por: Vaseghi, Golnaz, et al.
Publicado: (2022)

Sorafenib for Patients with Hepatocellular Carcinoma and Child‐Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study
por: Labeur, Tim A., et al.
Publicado: (2019)

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023)

Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma
por: Middleton, Gary
Publicado: (2020)

Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study
por: Lencioni, R, et al.
Publicado: (2010)

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
por: Peters, Brandilyn A., et al.
Publicado: (2019)

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
por: Hamilton, Erika, et al.
Publicado: (2022)

Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma
por: Pal, Harish C., et al.
Publicado: (2015)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
por: O’Shaughnessy, Joyce, et al.
Publicado: (2022)

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
por: Dirix, Luc Y., et al.
Publicado: (2017)

Chemotherapy use near the end-of-life in patients with metastatic breast cancer
por: Edman Kessler, Luisa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cf9aoojjmfcpsdtmk1rgjqpp1i